BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 37142051)

  • 21. Identification of
    Thein KZ; Biter AB; Banks KC; Duda AW; Saam J; Roszik J; Janku F; Skoulidis F; Heymach JV; Kopetz S; Meric-Bernstam F; Hong DS
    JCO Precis Oncol; 2022 Jul; 6():e2100547. PubMed ID: 35862868
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lung Adenocarcinoma: Predictive Value of KRAS Mutation Status in Assessing Local Recurrence in Patients Undergoing Image-guided Ablation.
    Ziv E; Erinjeri JP; Yarmohammadi H; Boas FE; Petre EN; Gao S; Shady W; Sofocleous CT; Jones DR; Rudin CM; Solomon SB
    Radiology; 2017 Jan; 282(1):251-258. PubMed ID: 27440441
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic value of epidermal growth factor receptor gene mutation in resected lung adenocarcinoma.
    Deng C; Zhang Y; Ma Z; Fu F; Deng L; Li Y; Chen H
    J Thorac Cardiovasc Surg; 2021 Sep; 162(3):664-674.e7. PubMed ID: 32747123
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of KRAS and EGFR gene mutations on recurrence and survival in patients with surgically resected lung adenocarcinomas.
    Sonobe M; Kobayashi M; Ishikawa M; Kikuchi R; Nakayama E; Takahashi T; Menju T; Takenaka K; Miyahara R; Huang CL; Okubo K; Bando T; Date H
    Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S347-54. PubMed ID: 21607772
    [TBL] [Abstract][Full Text] [Related]  

  • 25. KRAS mutational analysis and immunohistochemical studies can help distinguish pancreatic metastases from primary lung adenocarcinomas.
    Krasinskas AM; Chiosea SI; Pal T; Dacic S
    Mod Pathol; 2014 Feb; 27(2):262-70. PubMed ID: 23887294
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Therapeutic possibilities in KRAS-mutant lung adenocarcinoma].
    Radeczky P; Ghimessy Á; Berta J; László V; Hegedűs B; Rényi-Vámos F; Fillinger J; Megyesfalvi Z; Döme B
    Magy Onkol; 2020 Sep; 64(3):231-244. PubMed ID: 33196710
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Loss of wild type KRAS in KRAS
    Liu Y; Gao GF; Minna JD; Williams NS; Westover KD
    Lung Cancer; 2021 Mar; 153():73-80. PubMed ID: 33465697
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of real-life data from patients with NGS panel negative and
    Gökyer A; Küçükarda A; Köstek O; Gökmen İ; Özcan E; Sayın S; Taştekin E; Hacıoğlu B; Erdoğan B; Uzunoğlu S; Çiçin İ
    Tumori; 2022 Apr; 108(2):141-146. PubMed ID: 33624577
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A retrospective observational study of the natural history of advanced non-small-cell lung cancer in patients with KRAS p.G12C mutated or wild-type disease.
    Spira AI; Tu H; Aggarwal S; Hsu H; Carrigan G; Wang X; Ngarmchamnanrith G; Chia V; Gray JE
    Lung Cancer; 2021 Sep; 159():1-9. PubMed ID: 34293517
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer.
    Araujo LH; Souza BM; Leite LR; Parma SAF; Lopes NP; Malta FSV; Freire MCM
    BMC Cancer; 2021 Feb; 21(1):193. PubMed ID: 33632153
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review.
    Strickler JH; Yoshino T; Stevinson K; Eichinger CS; Giannopoulou C; Rehn M; Modest DP
    Oncologist; 2023 Nov; 28(11):e981-e994. PubMed ID: 37432264
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [To evaluate the clinicopathologic characteristics and outcome of tumor cells spreading through air spaces in patients with adenocarcinoma of lung].
    Sun PL; Liu JN; Cao LQ; Yao M; Gao HW
    Zhonghua Bing Li Xue Za Zhi; 2017 May; 46(5):303-308. PubMed ID: 28468034
    [No Abstract]   [Full Text] [Related]  

  • 33. Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer.
    Cui W; Franchini F; Alexander M; Officer A; Wong HL; IJzerman M; Desai J; Solomon BJ
    Lung Cancer; 2020 Aug; 146():310-317. PubMed ID: 32619782
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MUC5AC enhances tumor heterogeneity in lung adenocarcinoma with mucin production and is associated with poor prognosis.
    Dong Y; Zhou L; Zhao D; Li K; Liu Z; Che N; Liu H
    Jpn J Clin Oncol; 2020 Jun; 50(6):701-711. PubMed ID: 32083303
    [TBL] [Abstract][Full Text] [Related]  

  • 35. KRAS
    Kyriakopoulos G; Katopodi V; Skeparnias I; Kaliatsi EG; Grafanaki K; Stathopoulos C
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672357
    [TBL] [Abstract][Full Text] [Related]  

  • 36. KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population.
    Schirripa M; Nappo F; Cremolini C; Salvatore L; Rossini D; Bensi M; Businello G; Pietrantonio F; Randon G; Fucà G; Boccaccino A; Bergamo F; Lonardi S; Dei Tos AP; Fassan M; Loupakis F
    Clin Colorectal Cancer; 2020 Sep; 19(3):219-225. PubMed ID: 32605718
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metachronous primary lung adenocarcinomas harboring distinct KRAS mutations.
    Hu Y; Ren S; Chen C; Liang Q; Yu F; Liu W
    Thorac Cancer; 2020 Jul; 11(7):2018-2022. PubMed ID: 32415761
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
    Fiala O; Pesek M; Finek J; Benesova L; Belsanova B; Minarik M
    Cancer Genet; 2013; 206(1-2):26-31. PubMed ID: 23313110
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overall survival in patients with advanced non-small cell lung cancer with KRAS G12C mutation with or without STK11 and/or KEAP1 mutations in a real-world setting.
    Julian C; Pal N; Gershon A; Evangelista M; Purkey H; Lambert P; Shi Z; Zhang Q
    BMC Cancer; 2023 Apr; 23(1):352. PubMed ID: 37069542
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical relevance of PD-L2 expression in surgically resected lung adenocarcinoma.
    Takamochi K; Hara K; Hayashi T; Kohsaka S; Takahashi F; Suehara Y; Shimokawa M; Suzuki K
    Lung Cancer; 2022 Jun; 168():50-58. PubMed ID: 35489160
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.